Many studies suggest that a multi-tissue tumour suppressor gene is located at human chromosome 7q31.1. We have cloned and characterized a novel gene at this locus. The TES gene lies within the minimal region of overlap of several LOH studies and appears to possess the properties of a tumour suppressor. TES is widely expressed and is predicted to encode a protein of 421 amino acids, with three C-terminal LIM domains. Mutation analysis of the coding TES exons in 21 human tumour-derived cell lines revealed the presence of a frameshift mutation in one allele in the breast cancer cell line ZR-75. Methylation of the CpG island at the 5' end of TES appears to be a remarkably frequent ®nding, occurring in seven out of 10 ovarian carcinomas and in each of the 30 tumour-derived cell lines tested. Moreover, forced expression of TES in HeLa or OVCAR5 cells, resulted in a profound reduction in growth potential, as determined by the colony formation assay. We believe that TES is a tumour suppressor gene that is inactivated primarily by transcriptional silencing resulting from CpG island methylation. Oncogene (2001) 20, 2844 ± 2853.
Introduction
A large body of cytogenetic, molecular genetic and functional evidence supports the existence of a multitissue tumour suppressor gene (TSG) on the long arm of human chromosome 7. Karyotypic alterations of chromosome 7 are common in a variety of human tumour types. From those studies in which the extent of interstitial chromosomal deletions have been ascertained most precisely, it appears that deletions encompassing 7q31-32 are common in myeloid tumours (Pedersen and Ellegaard, 1994) , malignant andrological neoplasias (Atkin and Baker, 1993) , skin carcinoma, breast carcinoma and ovarian carcinoma . Further evidence has been provided by loss of heterozygosity (LOH) studies in sporadically occurring solid human tumours. These LOH studies, which have examined DNA from tumours of several dierent types, have reported frequent losses in the vicinity of 7q31.1 ± 31.2 ( Figure  1 ). For instance, LOH at this location was detected in 40 ± 83% of breast tumours (Bieche et al., 1992; Zenklusen et al., 1994a) and 83% of prostate tumours (Zenklusen et al., 1994c) , in 21 ± 59% of ovarian tumours (Edelson et al., 1997; Kerr et al., 1996; Koike et al., 1997; Zenklusen et al., 1995b) , and in 24 ± 30% of renal cell carcinomas (Shridhar et al., 1997) . In addition, LOH at this site was a frequent ®nding in colonic (Zenklusen et al., 1995a) , pancreatic (Achille et al., 1996) and gastric (Kuniyasu et al., 1994) carcinomas in addition to squamous cell carcinomas of the head and neck (Zenklusen et al., 1995a) .
Functional studies have provided additional data supporting the presence of a TSG in this region. For instance the tumorigenic activity of murine squamous cell carcinoma cells was found to be suppressed following the microcell-mediated introduction into these cells of human chromosome 7 (Zenklusen et al., 1994b) . Furthermore, the tumorigenic phenotype was observed to be regained in cells which had sustained a loss of the introduced chromosome (Zenklusen et al., 1994b) .
Here we describe the isolation and characterization of a candidate human TSG mapping within the chromosomal region speci®ed by the region of overlap of independent published tumour LOH studies. This gene, whose cDNA was isolated from a human senescent ®broblast library, is predicted to encode a protein of 421 amino acids, sharing 86% identity at the amino acid level with the murine Tes-2 gene product and which contains three LIM domains. Mutation analysis by single-strand conformational polymorphism (SSCP) of the coding sequence in 21 tumour-derived cell lines and 42 primary ovarian carcinoma DNA samples revealed the presence of a frame-shift mutation in one allele of a breast cancer cell line and polymorphisms in a number of samples. However, from a subsequent analysis of methylation of the gene in a series of tumour-derived cell lines and ovarian tumour samples it appears that this epigenetic modi®cation may represent a frequent mechanism by which the gene is inactivated during tumourigenesis. Moreover, we report a profound inhibition of growth potential that was observed in tumour cells following transfection with TES expression constructs.
Results

Cloning cDNAs from 7q31
On the assumption that a single TSG residing at 7q31 is responsible for the relatively high frequency of LOH found in the various tumour types described above, we used the regions of LOH identi®ed in the individual studies, in addition to our own unpublished data, to de®ne a minimal area of overlap¯anked by the Genethon microsatellite markers D7S486 and D7S655 (Figure 1) . In order to identify likely candidate TSGs lying within this region, we conducted a search of the human gene map of this region provided by the online Science database at NCBI. Each of the Expressed Sequence Tags (ESTs) that were identi®ed as being located within the delineated minimal area of overlap was then used to undertake a Blast search of the GenEMBL database in order to obtain overlapping homologous EST or cDNA sequences and thus permit the extension of the sequence in the 5' direction. Oligonucleotide PCR primers were designed speci®c for each EST sequence contig, thus permitting extensive rtPCR, cDNA hybridization and sequence analysis to be carried out on a senescent human ®broblast cDNA library. Products were isolated for two clusters, corresponding to the markers WI-8726 (D7S2787) and SHGC-10385. The sequence represented by the marker SHGC-10385 was found to correspond to the 3' end of the CAVEOLIN-1 gene, thus establishing the map position of this human gene. Despite previously reported limited in vitro data suggesting a tumour suppressor function for CAVEOLIN-1, subsequent SSCP, methylation, and expression analysis of this gene, performed in our laboratory, failed to reveal any abnormalities in human tumours or tumour-derived cell lines (Hurlstone et al., 1999) . In addition, however, two positive cDNA clones were obtained following hybridization with the WI-8726 cDNA probe and these were isolated and sequenced. Following the assembly of the sequence fragments obtained from both cDNA clones and subsequent editing, the cDNA sequence contig was analysed for the presence of open reading frames (ORFs). A continuous ORF of 1263 nucleotides was found between nucleotides 129 and 1391 of the cDNA sequence (GenBank accession no. AJ250865). The sequence surrounding the ATG start codon ful®ls the criteria established by Kozak (1996) , and the coding sequence is conserved in EST clones from mouse, rat and zebra®sh (data not shown). An elongated 3' untranslated region of 1305 nucleotides was found with a polyadenylation signal residing at position 2675. The 128-nucleotide 5' untranslated region contains 14 CpG dinucleotides, indicating that this gene is associated with a CpG island.
Blast and FastA searches of the Swissprot and TrEMBL databases revealed both a mouse and C.
elegans homologue of the protein. The predicted human amino acid sequence was found to share 86% identity with the mouse Tes-2 sequence (Divecha and Charleston, 1995) (GenBank accession no. 1351218) Figure 1 Regions exhibiting loss of heterozygosity in a range of tumour types at human chromosome 7q31.1. Chromosome 7 is depicted as an ideogram showing cytogenetic banding. Alongside are shown the polymorphic STSs used to determine the extent of allele loss. The solid vertical bars represent the regions of LOH, relative to the STS markers shown, de®ned by the following tumour studies: (1) Head and neck squamous cell carcinoma, 53% LOH (Zenklusen et al., 1995a) , (2) Prostate, 83% (Zenklusen et al., 1994c) , (3) Pancreas, 80% (Achille et al., 1996) , (4) Ovary, 50% (Koike et al., 1997) , (5) Renal cell carcinoma, 64% (Shridhar et al., 1997) , (6) Ovary, 59% (Edelson et al., 1997) , (7) Breast, 83% (Zenklusen et al., 1994a) . Diagonally hatched bars have been used to indicate regions within which a boundary of LOH lies, where it is not possible to determine the precise limit of the LOH relative to the encompassed markers and 36% identity with a putative peptide encoded by DNA sequence derived from chromosome III of C. elegans (Wilson et al., 1994) (GenBank accession no. 1326362) (Figure 2 ). Sequence alignment using the ClustalW program revealed that the highest degree of identity between the mammalian and nematode proteins is present in the C-terminal regions of the proteins. In addition using the Pfam program provided by the Sanger Centre it was ascertained that the predicted human protein sequence, like the murine sequence, contains three LIM domains, highly conserved cysteine-rich, zinc-binding domains of approximately 60 amino acids (Perez-Alvarado et al., 1994) , located between residues 236 ± 298, 301 ± 358 and 361 ± 421 (Figure 3) . From here on we will refer to this gene as TES.
TES gene expression
We investigated the tissue distribution of the TES transcript by two methods: ®rstly, a blastn search against the human EST database revealed over 100 matches, corresponding to the Unigene cluster Hs. 165986 (http: // www.ncbi.nlm.nih.gov / UniGene / clust.cgi?ORG=HsandCID=165986). The clones in this cluster have been isolated from bone, breast, germ cell, heart, kidney, lung, muscle, ovary, pancreas, parathyroid, prostate, spleen, stomach, testis, thyroid and uterus cDNA libraries, indicating that the TES gene is expressed in a wide variety of tissues. We carried out further expression analysis of TES, by probing a multi-tissue Northern blot with the TES cDNA. An approximately 2.8 kb transcript is seen in all lanes, with strong expression in heart, placenta, lung, kidney and pancreas, and weak expression in brain, liver and skeletal muscle (not shown).
Genomic structure and mutational analysis of TES We determined the genomic structure of the TES gene, in order to obtain intron sequence, adjacent to the TES exons. This was required for us to amplify the exons from genomic DNA for mutation analysis by single-strand conformation polymorphism and direct sequencing. The longer of the two cDNA clones was excised from Bluescript using an EcoRI/XhoI restriction digest and the insert cDNA was radio-labelled and utilized to screen a human chromosome 7-speci®c cosmid array. By this means a hybridizing cosmid (E2454Q4) was identi®ed and the corresponding clone obtained, from the Resource Centre of the German Human Genome Project, which fortuitously appeared to contain the entire coding region of the gene. In order to ascertain the location of the exon/intron boundaries and the neighbouring intron sequences, exon-speci®c PCR primers were designed and used to sequence directly from the cosmid DNA template. The locations and partial DNA sequences of six introns were thus determined.
Mutation analysis was subsequently undertaken by SSCP using intron-speci®c primers encompassing each exon in turn on a variety of human DNA templates. These consisted of DNA samples extracted from 21 tumour cell lines, and from 42 paired normal and tumour tissue samples. We identi®ed sequence variants in various samples, but most of these were due to polymorphisms in the intron sequence included in the ampli®ed products. The sequence changes identi®ed in the TES exons are shown in Table 1 . All of these are silent changes, with the exception of a 1186insT mutation in the breast tumour cell line ZR-75. This mutation causes a frameshift at codon 353 resulting in a premature stop at codon 378. If translated, this allele would be expected to encode a TES variant lacking the third LIM domain and with possible disruption of the C-terminal end of the second LIM domain.
Suppression of clonal outgrowth by TES
Attempts to generate cell lines that stably expressed TES were unsuccessful. Very few clones were found that express full-length TES protein and, those that did, rapidly lost expression (data not shown). This phenomenon was observed with a number of dierent 
The TES CpG island is methylated in tumour derived cell lines and in primary tumours
Transcriptional silencing by methylation during tumour progression has been described for several genes possessing CpG islands. In fact, an increasing body of evidence supports methylation as an important epigenetic mechanism of tumour suppressor gene inactivation in both familial and sporadic tumours (as recently reviewed by Baylin and Herman, 2000) . In the case of CDKN2A, for example, methylation may be the most common mechanism whereby this gene is inactivated in tumours (Herman et al., 1995) . Consequently, we decided to look at the methylation status of TES in DNA from several primary ovarian tumours as well as the cell lines previously analysed for mutations in order to determine whether methylation occurred and its frequency.
Genomic DNA samples from the 30 tumour-derived cell lines indicated in Table 2 were restriction digested with either HpaII (which has the recognition sequence CCGG, but will not cleave DNA if the second cytosine residue is methylated on the 5-position) or MspI (which cleaves DNA at the same sites as HpaII regardless of methylation). Restriction digested DNA was hybridized on a blot with a probe corresponding to nucleotides 140 ± 1400 of TES. In all the cell lines tested, four bands were seen in the MspI digests, ranging in size from 250 to 5 k bp. However, only a single high molecular weight band, running at limiting mobility in the gel, was seen in the HpaII digests, indicating that the DNA is methylated (Figure 5a ). As a control for digestion, the ®lters were also probed with exon 1 of CAVEOLIN-1 (Figure 5b ) which is cleaved at multiple sites by HpaII (Hurlstone et al., 1999) . In all instances the pattern of hybridization was essentially the same for DNA tracts digested with either HpaII or MspI, indicating that the restriction digests were complete and that in no instance did exon 1 of CAVEOLIN-1 appear to be methylated. We also investigated the methylation status of the TES gene in 10 primary ovarian tumours, using the blots prepared previously (Hurlstone et al., 1999) . DNA samples were restriction digested with EcoRV/HindIII alone or with EcoRV/HindIII in combination with either HpaII or MspI and hybridized with a probe corresponding to part of the 5' CpG island (nucleotides 1 ± 390) of the TES gene. Results are shown for these tumours in Figure 6a . In tumours 1, 6 and 8 there is an identical pattern, of a single 3 kbp band in both the HpaII and MspI digests, indicating that the DNA is unmethylated. In the other seven samples (numbers 2, 3, 4, 5, 7, 9 and 10), high molecular weight bands are seen in the HpaII digests, indicating that the TES 5' CpG island is methylated in these tumours. The same blots probed with exon 1 of CAVEOLIN-1 gave identical patterns for both the HpaII and MspI digests, showing that the restriction digests were complete (Figure 6b and see Hurlstone et al., 1999) .
Discussion
A gene mapping to chromosome 7q31.1 has been implicated in tumour suppression and cellular immortalisation . At this locus, incidences of LOH as high as 83% have been detected in human breast carcinomas (Zenklusen et al., , implying that the chromosome 7 tumour suppressor gene is a very frequently inactivated target during carcinogenesis. Independently, a gene implicated in replicative senescence, the immortality complementation group D gene, has also been mapped to the 7q31.1 chromosomal region (Ogata et al., 1993) , raising the possibility that the tumour suppressor gene and the immortality complementation group D gene are one and the same. We have used a positional cloning strategy to identify this locus, by characterising ESTs which map to the minimal region of deletion in tumours. This analysis has led to the identi®cation of the TES gene, a novel human gene, predicted to encode a protein with a high degree of identity to the murine gene, Tes-2. TES encodes a 421 amino acid protein with three Cterminal LIM domains. LIM domains each consist of two zinc ®ngers, linked by a two-amino acid spacer. They are found in a variety of proteins with diverse functions and sub-cellular distributions, including proto-oncogene products and transcription factors. Two classes of such proteins exist: those which contain LIM domains only (LIM-only proteins) such as Rbtn2, an oncoprotein essential for erythroid dierentiation (Warren et al., 1994) , and those containing LIM domains in addition to a DNA-binding homeodomain (LIM homeodomain proteins: recently reviewed by Hobert and Westphal (2000) ). The latter include the LMX1B transcription factor, mutations in which cause nail-patella syndrome (Dreyer et al., 1998) .
The vast majority of LIM-only proteins possess only one or two LIM domains. TES, however, like the cytoskeletal protein, ZYXIN, belongs to a sub-group of LIM-only proteins which each contain three Cterminal LIM domains and possess an amino terminal proline-rich region (Figure 7) . These triple LIM domain proteins include ZYXIN, ZYXIN-related protein (ZRP-1), lipoma preferred partner (LPP) and ENIGMA. ZYXIN, a member of the focal adhesion complex, binds cysteine-rich protein (CRP), which is another LIM-only protein, through its ®rst LIM domain and also to alpha-actinin and the human proto-oncogene product VAV (Hobert et al., 1996; Schmeichel and Beckerle, 1994) through its N-terminal proline-rich region. ZRP-1 interacts with a PDZ domain of the cytosolic protein tyrosine phosphatase hPTP1E (Murthy et al., 1999) , and has an identical genomic organisation to that of LPP, suggesting their common evolution from a recent gene duplication. ENIGMA interacts with the insulin receptor through its third LIM domain (Wu and Gill, 1994) and with the receptor tyrosine kinase, RET, through its second LIM domain (Wu et al., 1996) . Thus members of this subfamily of LIM-only proteins, which by homology includes TES, appear to be mediators of intracellular signalling, as well as being determinants of cytoskeletal and adhesion complex organization. These proteins may thus in¯uence cell growth and survival, and cellular adhesion, which are both aspects of cell behaviour that become altered during tumorigenesis. We are currently investigating the biochemical function of TES through searching for interacting protein partners.
Another LIM-only protein, encoded by the TGF-b1 induced gene HIC-5, is believed to play a role in growth inhibition. The C-terminal region of HIC-5, which contains seven zinc-®nger motifs, has, in fact, been reported to mediate both targeting to focal adhesions (Matsuya et al., 1998) , and, even according to one study, speci®c DNA binding (Nishiya et al., 1998) . Its expression was reported to be increased upon the induction of replicative senescence in human ®broblasts and to be reduced in nine out of 10 tested tumour-derived cell lines (Shibanuma et al., 1994) . Moreover, ectopic expression of this gene in immortalized ®broblasts resulted in reduced colony-forming eciency and appeared to induce senescence, while expression of anti-sense HIC-5 in normal ®broblasts delayed senescence (Shibanuma et al., 1997) . Intriguingly, the two immortalized human cell lines whose growth rates were reduced upon HIC-5 expression (Shibanuma et al., 1997) were KMST-6 and SUSM-1. These ®broblast-derived cell lines have both been assigned (Ogata et al., 1993) to the immortality complementation group D mentioned above. It is possible, therefore, that TES, whose C-terminal half exhibits structural similarity to that of HIC-5 ( Figure  7) , and is encoded by a gene residing at the locus, 7q31.1, to which the group D gene has been mapped (Ogata et al., 1993) , may, itself, play a pivotal role in replicative senescence.
In this study, we found little evidence for micro-scale mutational inactivation of TES despite performing SSCP analysis on genomic DNA samples prepared from a number of tumour-derived cell lines (and also by sequencing TES cDNA prepared from a subset of them), with the exception of a T insertion mutation in the breast carcinoma cell line ZR-75. Additionally, we did not ®nd evidence of any gross alterations or homozygous deletions of the gene by Southern blot analysis, or of altered transcript size by RT-PCR (data not shown). We have demonstrated, however, that the level of expression of TES is likely to be subject to epigenetic modi®cation by methylation in several of these cell lines and in primary ovarian tumours. Methylation of the promoter region of a gene is frequently correlated with its transcriptional downregulation and there is an increasing body of evidence supporting the importance of the inactivation of . For instance, BRCA1 promoter hypermethylation was recently reported to occur in 55 and 67% of sporadic mucinous and medullary breast carcinomas, respectively (Esteller et al., 2000) , while hypermethylation of the E-CADHERIN gene promoter was observed in 83% of sporadic gastric carcinomas of the undierentiatedscattered type (Tamura et al., 2000) . Furthermore, hypermethylation of the hMLH1 gene promoter has been detected in 32% of sporadic human gastric carcinomas and in 78% of those showing microsatellite instability (MSI) (Fleisher et al., 1999) . We considered, therefore, that if TES were indeed a tumour suppressor gene in vivo, this mechanism could represent the means by which the gene becomes inactivated during tumourigenesis. Here we con®rmed that the CpG island associated with the 5' end of TES is methylated in the majority of primary ovarian tumours and in each of the tumour-derived cell lines tested.
In addition, Northern analysis of RNA samples isolated from a panel of squamous cell tumour cell lines, cultured in the presence or absence of the methylation inhibitor, 5-azacytidine, has con®rmed that the degree of methylation of TES is, indeed, inversely correlated with the transcript level of the gene (data not shown). The resistance to HpaII digestion of the DNA of tumours 2, 3, 4, 5, 7, 9 and 10 ( Figure 6 ) and of the DNA of all the tumour cell lines examined ( Figure 5 ) strongly suggests that hypermethylation of the TES promoter occurs on both alleles. Biallelic TSG promoter methylation has, in fact, been demonstrated previously for the mismatch repair gene hMLH1, in sporadic colorectal and gastric cancer, and is a wellrecognised transcriptional silencing mechanism (Fleisher et al., 1999; Veigl et al., 1998) . Moreover, the methylation of hMLH1 in these colorectal tumours was detected in the absence of hMLH1 mutations and was shown to be the means by which the gene was inactivated (Veigl et al., 1998) .
In order to determine whether expression of wild type TES might attenuate the proliferative potential of tumour cells, we transfected OVCAR5 and HeLa cells with TES expression constructs. Following geneticin selection, a profound reduction in colony formation was observed in cells transfected with vectors encoding full-length TES, relative to those cells transfected with the empty vector. Moreover, the absence of TES expression in cells continuing to proliferate following post-transfection selection (immunoblotting results not shown), and the inability to generate cell lines that stably express TES, constitute additional evidence of the ability of TES to suppress cell proliferation. The growth suppression is, in fact, similar to that previously observed for the related protein, HIC-5 (Shibanuma et al., 1997) , and for several known TSG products including pRb, p53 and p16, using the colony formation assay (Costanzi-Strauss et al., 1998) . It lends considerable support to the possibility that TES represents a critical novel TSG that is inactivated by promoter hypermethylation and that this gene accounts for the high frequency of LOH previously observed at 
Materials and methods
Preparation of TES cDNA probes PCR was carried out on an MJ Research PTC-200 thermal cycler (Genetic Research Instrumentation Ltd., UK). The oligonucleotide primer sequences used to amplify the STS sequences were as follows: WI-8726: CATAGTGCATAGC-TATGTG (Forward) and AATCAAAAGCCAAGCCACCC (Reverse); SHGC-10385: TTTAAAACAGACACTGGCAT-GG (For.) and AGTTTACAGATTGAATCACAAAGCC (Rev.). Each reaction was carried out using 1 mg total HeLa DNA or 1 ml phage supernatant containing 10 8 pfu of a human senescent ®broblast cDNA library (prepared by Dr G Reid using ZAP ± cDNA Gigapack II synthesis kit (Stratagene, UK)), 1 mm oligonucleotide primers, 1x reaction buer, 1.5 mM MgCl 2 , 1 unit Taq DNA polymerase (Bioline, UK), and 100 mM dNTPs in a total reaction volume of 25 ml. The cycling parameters consisted of 30 cycles, each comprising three steps: 94.08C for 60 s, 55.08C for 30 s and 72.08C for 30 s. Following ampli®cation, a 10 ml aliquot was loaded onto a 2% agarose gel alongside an aliquot of fX174/HaeIII restriction fragments and resolved by electrophoresis. DNA was detected by ethidium bromide staining and UV transillumination.
Screening the human senescent fibroblast cDNA library
Probes were made utilising 25 ng of puri®ed PCR products radiolabelled with 50 mCi of a 32 P-dCTP (Amersham International plc., UK) using a random-priming labelling kit (HighPrime, Bohreinger Mannheim, UK). The human senescent ®broblast cDNA library (above) was plated onto Hybond-N nylon membranes (Amersham). Following pre-hybridization at 658C for 4 h in hybridization buer (56SSPE, 56Den-hardt's, 0.5% (w/v) SDS, 1 mg/ml Torula yeast RNA type VI), the membranes were incubated overnight at 658C in fresh hybridization buer containing the radiolabelled cDNA probe. Membranes were washed twice in 0.2 6SSC/0.1% (w/v) SDS for 30 min at 658C and then exposed to X-ray ®lm (X-OMAT-AR, Kodak, USA) overnight at 7708C in a ®lm cassette containing an intensifying screen. Further rounds of plating and cDNA hybridization were carried out to isolate the positively hybridizing phage and in vivo excision of the pBluescript phagemid was undertaken using the ExAssist helper phage supplied with the ZAP ± cDNA Gigapack II kit. Phagemid DNA was prepared in larger quantities by incubating with SOLR cells and growing in L-broth containing ampicillin (50 mg/ml). DNA was extracted by alkaline lysis and puri®ed by CsCl gradient centrifugation and ethanol precipitation (Maniatis et al., 1989) .
DNA sequencing
Sequencing of cDNA inserts was performed by the dideoxy chain termination method, using the ABI PRISM dye terminator cycle sequencing kit (PE Applied Biosystems, UK) and 25 ng oligonucleotide primers. Dye-labelled products were resolved and detected using the Applied Biosystems ABI373 DNA sequencer. Sequence was analysed using the Sequencing Analysis program v3.0. The primers used were the pBluescript SK and KS speci®c sequences, initially, and the cDNA primer sequences were subsequently chosen at intervals of approximately 200 bp in order to produce a set of overlapping sequence fragments for each strand.
Sequence analysis
Sequence assembly, editing, mapping and reading frame analysis was undertaken using the Wisconsin GCG package running on a local Sun workstation. Homology searches of Genbank and Swissprot databases were carried out using the Blast algorithm at the NCBI (http://www.ncbi.nlm.nih.gov/ BLAST/), multiple protein sequence alignments were performed using the ClustalW program at the HGMP website (http://www.hgmp.mrc.ac.uk/) and identi®cation of protein motifs undertaken using the Pfam algorithm at the Sanger Centre website (http://www.sanger.ac.uk/Software/Pfam/).
Screening a human cosmid library
The cDNA insert was excised by an EcoRI/XhoI restriction digest from the larger of the two phagemid clones corresponding to WI-8726 that were isolated. This cDNA fragment was puri®ed, radiolabelled and then incubated with prehybridized Nylon membranes supporting an array of clones representing a human chromosome 7-speci®c genomic cosmid DNA library (Resource Centre of the German Human Genome Project) as described above. A positive hybridization signal was obtained with clone E2454Q4, which was subsequently requested from the RCGHP.
Determination of exon/intron boundaries
DNA sequencing of cosmid DNA was performed as described above, with the exception that 10 mg of DNA was used as template. Exon/intron boundaries were located by analysis of the alignments (created using GCG) between genomic DNA sequence and the corresponding cDNA sequences.
SSCP analysis of TES in tumour and cell line DNAs
Intron-speci®c oligonucleotide primers (Table 3) , corresponding to exons 2 ± 7 of TES, were used to perform PCR, using as template 100 ng of genomic DNA from 21 tumour-derived cell lines and 42 ovarian carcinomas, prepared according to a previously described method (Laird et al., 1991) . The reaction conditions were as described above, with the addition of 1 mCi a 32 P-dCTP per reaction. Subsequently, 4 ml of PCR product was mixed with 8 ml of STOP buer (95% formamide, 200 mM EDTA pH 8.0, 0.01% (w/v) xylene cyanol and bromophenol blue), denatured by heating at 948C for 8 min and quenched on wet ice. Three ml was then resolved in a 6% non-denaturing polyacrylamide gel containing 5% glycerol. Gels were ®xed by heating at 808C under vacuum, and exposed directly to X-ray ®lm for detection by autoradiography.
Analysis of TES CpG methylation using MspI and HpaII digested tumour and cell line DNAs From each of 10 primary human ovarian carcinomas and from our panel of 30 tumour-derived cell lines, 10 mg genomic DNA was digested with HpaII and with MspI and then resolved by electrophoresis on a 1% agarose gel. Subsequently, DNA was transferred onto Hybond N+ nylon membrane (Amersham International plc, UK) according to the manufacturer's instructions. Genomic DNA blots were pre-hybridized, probed and visualized as above. For the ovarian carcinomas the cDNA probe used was a radiolabelled 390 bp TES XmnI/EcoRI cDNA fragment containing the TES CpG island and a full-length TES PCR product was used to probe the cell line DNAs.
Transfection and clonogenic assays
The full-length TES coding cDNA (amino acids 1 ± 421) was ampli®ed with primers (cataggatccgttaacatggacctgga and gtgccctcgagctaagacatcctc) containing appropriate restriction sites italicized). The BamHI/XhoI-digested product of the reaction was then cloned into the BamHI/XhoI-digested pcDNA3.1/HisC eukaryotic expression vector (Invitrogen) in a sense orientation and the construct was subsequently sequenced to con®rm the absence of PCR-generated mutations. In each experiment, 6610 6 cells in a 100-mm diameter dish were transfected with 2 ug of plasmid DNA using lipofectamine as recommended by the manufacturer. After incubation for 48 h at 378C, transfected cells were trypsinized and seeded onto 100-mm dishes at a density of 1610 5 cells per dish. Selection medium containing G418 (400 ug/ml) was added. Two weeks later, colonies were ®xed in methanol, stained by 10% Giemsa, and counted. To control for DNA quality, each experiment was repeated with a freshly prepared batch of plasmid DNA.
